Trulieve Cannabis Corp. income statement TRLV

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Trulieve Cannabis Corp. reported revenue of $1.2 billion, down 0.4% from the year before. It recorded a net loss of $122.2 million. Operating income came to $143.5 million, an operating margin of 12.1%. Diluted earnings per share were -$0.58. Over the twelve months ended Sep 30, 2026, revenue was $1.1 billion and the net loss was $446.6 million. Across the 5 fiscal years shown, revenue grew from $931.9 million in fiscal 2021 to $1.2 billion in fiscal 2025, about 6.1% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
1,081
-9.1%
1,181
-0.4%
1,186
+5.1%
1,129
-7.3%
1,218
+30.7%
932
Cost of revenue
426
-8.7%
470
-0.2%
471
-12.9%
541
+2.2%
529
+44.8%
365
Gross profit
656
-9.3%
711
-0.6%
716
+21.6%
589
-14.6%
689
+21.6%
567
Selling, general and administrative
421
445
-12.8%
510
+32.2%
386
-13.6%
447
+43.6%
311
Operating income
-277
-313.9%
143
+46.8%
98
+144.1%
-222
-541.8%
50
-75.4%
204
Other income (expense)
-51
+5.0%
-52
+5.5%
-55
+12.5%
-63
+9.3%
-69
-149.6%
-28
Pretax income
-328
-534.0%
91
+114.2%
43
+115.0%
-285
-1379.0%
-19
-110.9%
176
Income tax
118
-43.2%
208
+5.3%
198
+30.5%
151
-7.4%
163
+12.1%
146
Net income
-447
-218.5%
-122
+23.9%
-161
+69.9%
-533
-111.0%
-253
-1548.7%
17
Net income to common
-446
-234.4%
-116
+25.0%
-155
+70.6%
-527
-114.1%
-246
-1464.6%
18
Basic EPS
-2.32
-231.6%
-0.58
+26.6%
-0.79
+65.4%
-2.28
-140.0%
-0.95
-531.8%
0.22
Diluted EPS
-2.32
-231.6%
-0.58
+26.6%
-0.79
+65.4%
-2.28
-140.0%
-0.95
-552.4%
0.21
Weighted average shares, basic
192
+0.8%
191
+0.7%
190
+0.5%
189
+0.5%
188
+34.9%
139
Weighted average shares, diluted
192
+0.8%
191
+0.7%
190
+0.5%
189
+0.5%
188
+28.1%
147
Other measures
Depreciation and amortization
103
-12.2%
118
+4.3%
113
+2.7%
110
-5.6%
116
+154.2%
46
EBITDA
-174
-170.8%
261
+24.0%
211
+288.4%
-112
-167.1%
167
-33.3%
250
Interest coverage
-5.25x
2.26x
1.57x
—
—
—
Margins
Gross margin
60.64%
60.21%
60.32%
52.13%
56.57%
60.80%
Operating margin
-25.62%
12.15%
8.24%
-19.63%
4.12%
21.90%
Pretax margin
-30.36%
7.74%
3.60%
-25.20%
-1.58%
18.91%
Profit margin
-41.31%
-10.35%
-13.53%
-47.21%
-20.75%
1.87%
EBITDA margin
-16.13%
22.11%
17.75%
-9.90%
13.67%
26.81%
Effective tax rate
—
227.51%
462.59%
—
—
82.68%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as
TRLV (NYSE)
Fiscal year ends
December 31
Incorporated in
British Columbia, Canada
Headquarters
Tallahassee, FL
SEC filer status
Large accelerated filer
SEC CIK
1754195

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.